Activation of Nrf2/ARE pathway by Anisodamine (654-2) for Inhibition of cellular aging and alleviation of Radiation-Induced lung injury

[Display omitted] •The study investigated the protective effect of 654-2, a potential therapeutic compound, on radiation-induced lung injury.•Treatment with 654-2 resulted in reduced DNA damage and cellular senescence in lung tissue and alveolar epithelial cells.•654-2 activated the Nrf2/ARE pathway...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2023-11, Vol.124, p.110864-110864, Article 110864
Hauptverfasser: Guo, Haochun, Chen, Jiajia, Yu, Hanxu, Dong, Lei, Yu, Ran, Li, Qingju, Song, Jian, Chen, Haoyu, Zhang, Haijun, Pu, Juan, Wang, Wanpeng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •The study investigated the protective effect of 654-2, a potential therapeutic compound, on radiation-induced lung injury.•Treatment with 654-2 resulted in reduced DNA damage and cellular senescence in lung tissue and alveolar epithelial cells.•654-2 activated the Nrf2/ARE pathway, leading to increased expression of antioxidant genes such as NQO1 and HO-1. Radiation-induced lung injury (RILI) is a common side effect of thoracic tumor radiotherapy, including early-stage radiation-induced lung injury (RP) and late-stage radiation-induced pulmonary fibrosis (RIPF). Currently, it is urgently needed to clarify the pathogenesis of RILI and find safe and effective RILI treatment methods. Irradiation causes DNA damage and oxidative stress in tissues and cells, induces cellular senescence, and promotes the occurrence and development of RILI. In recent years, Anisodamine (654-2) has shown potential therapeutic value in acute lung injury, acute kidney injury, chlamydial pneumonia, and COVID-19. However, there is currently no research on the mechanism of 654-2-mediated cellular senescence and its preventive and therapeutic effects on RILI. This study aimed to investigate the protective effect and mechanism of 654-2 on X-ray-induced RILI. In vivo experiments involved a mouse RILI model with 18 Gy X-ray irradiation. Mice were divided into control, model, medication (control + 654-2), and treatment (model + 654-2) groups. And mice in medication and treatment groups were intraperitoneal injection of 5 mg/kg 654-2 every other day until being sacrificed at week 6. In vitro experiments used MLE-12 cells irradiated with 16 Gy and divided into control, model, and model + 654-2(2 μM and 10 μM) groups. Various assays were performed to evaluate lung tissue morphology, fibrosis, apoptosis, cytokine expression, cellular senescence, protein expression, and antioxidant capacity. 654-2 mitigated pulmonary pathological damage, inflammation, DNA damage, cellular senescence, and apoptosis in RILI mice and MLE-12 cells. It restored epithelial cell proliferation ability and enhanced antioxidant capacity. Additionally, 654-2 activated the Nrf2/ARE pathway, increased Nrf2 phosphorylation, and upregulated antioxidant gene expression. Inhibition of Nrf2 reversed the effects of 654-2 on ROS production, antioxidant capacity, and cell senescence. 654-2 can activate the Nrf2/ARE pathway, enhance cellular antioxidant capacity, and inhibit cellular senescence, thereby exerting a p
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2023.110864